Alphonse Ouedraogo, Amidou Diarra, Issa Nébié, Nouhoun Barry, Jean Moise Kabore, Alfred B Tiono, Shrimati Datta, Yuanyuan Liang, Ifayet Mayo, Jennifer Oshinsky, J Kathleen Tracy, Tsion Girmay, Marcela Pasetti, Leslie P Jamka, Kathleen M Neuzil, Sodiomon B Sirima, Matthew B Laurens
We assessed anti-Vi IgG/IgA responses to typhoid conjugate vaccine (TCV) in children enrolled in a double-blind randomized, controlled, phase 2 trial in Burkina Faso. Anti-Vi IgG seroconversion and anti-Vi IgA titers were higher in TCV than control recipients at 30-35 months post-vaccination. TCV induces durable immunity in Burkinabe children vaccinated at 15-months.
Click here to read the entire article on the Journal of the Pediatric Infectious Disease Society.